Want to see IN:CAMLINFINE full AI Analyst Report?
Top Page
Camlin Fine Sciences Limited
(CAMLINFINE)
Select Model
Select Model
Rating:42Neutral
Price Target:
₹110.00
▼(-14.83% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial quality (sharp FY2026 revenue contraction, compressed margins, and especially inconsistent/negative free cash flow) and bearish technicals (price below major moving averages and negative MACD). Valuation further pressures the score due to an extremely high P/E, with no dividend yield data to offset it.
Positive Factors
Diversified specialty-ingredient platform
Exposure to multiple end markets and recurring B2B ingredient demand can reduce reliance on any single customer sector. Customized blends and application know-how may also support customer retention and differentiation over time.
Negative Factors
Sharp revenue contraction
The steep FY2026 revenue decline indicates substantial demand, portfolio, or execution volatility. Persistent contraction would weaken operating scale, reduce customer momentum, and make recovery in margins and cash generation more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified specialty-ingredient platform
Exposure to multiple end markets and recurring B2B ingredient demand can reduce reliance on any single customer sector. Customized blends and application know-how may also support customer retention and differentiation over time.
Read all positive factors
Camlin Fine Sciences Limited (CAMLINFINE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹19.90B
Dividend Yield0.47%
Average Volume (3M)60.53K
Price to Earnings (P/E)391.1
Beta (1Y)0.69
Revenue Growth8.40%
EPS GrowthN/A
CountryIN
Employees624
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.26
Shares Outstanding192,096,620
10 Day Avg. Volume46,121
30 Day Avg. Volume60,532
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.76
Price to Sales (P/S)1.06
P/FCF Ratio-55.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.55
Revenue Forecast (FY)₹22.03B
Camlin Fine Sciences Limited Business Overview & Revenue Model
Company Description
Camlin Fine Sciences Limited, an India-based company headquartered in Mumbai and established in 1931 (originally as Camlin Fine Chemicals Limited until August 2011), is involved in the global research, development, production, and distribution of ...
How the Company Makes Money
Camlin Fine Sciences primarily makes money by manufacturing and selling specialty ingredient chemicals and ingredient blends to business customers (B2B). Its main revenue stream is product sales from its ingredient portfolio—particularly antioxida...
Camlin Fine Sciences Limited Financial Statement Overview
Summary
Income Statement
43
Neutral
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.62B | 17.23B | 16.67B | 15.95B | 16.82B | 14.04B |
| Gross Profit | 5.83B | 4.86B | 7.78B | 6.58B | 8.41B | 6.34B |
| EBITDA | 833.43M | 954.20M | 1.95B | 487.60M | 1.84B | 1.79B |
| Net Income | 58.82M | 276.27M | -1.39B | -927.53M | 521.06M | 606.78M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 23.24B | 20.24B | 19.52B | 20.60B | 18.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.09B | 1.53B | 1.92B | 812.28M | 951.90M | 1.29B |
| Total Debt | 0.00 | 7.20B | 6.81B | 6.83B | 8.01B | 6.46B |
| Total Liabilities | -10.01B | 13.23B | 11.49B | 10.95B | 12.36B | 10.35B |
| Stockholders Equity | 10.01B | 10.41B | 9.02B | 8.65B | 8.19B | 7.48B |
Cash Flow | ||||||
| Free Cash Flow | 374.83M | -330.85M | -157.24M | 784.06M | -934.11M | -683.40M |
| Operating Cash Flow | 671.39M | 244.81M | 267.23M | 1.39B | 508.98M | 1.45B |
| Investing Cash Flow | -160.19M | -559.23M | -753.50M | -664.98M | -1.25B | -2.49B |
| Financing Cash Flow | -677.54M | 359.26M | 724.43M | -859.72M | 596.58M | 1.36B |
Camlin Fine Sciences Limited Technical Analysis
Negative
129.15
Price Trends
117.53
Negative
122.63
Negative
132.31
Negative
Market Momentum
-4.31
Negative
38.83
Neutral
65.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Negative. The current price of 129.15 is above the 20-day moving average (MA) of 105.23, above the 50-day MA of 117.53, and below the 200-day MA of 132.31, indicating a bearish trend. The MACD of -4.31 indicates Negative momentum. The RSI at 38.83 is Neutral, neither overbought nor oversold. The STOCH value of 65.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAMLINFINE.
Camlin Fine Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹68.51B | 48.10 | ― | 0.23% | 91.44% | 19.67% | |
65 Neutral | ₹32.67B | 47.89 | ― | 0.79% | 0.96% | -28.98% | |
63 Neutral | ₹21.42B | 6.44 | ― | 2.31% | -97.40% | -74.70% | |
62 Neutral | ₹34.08B | 0.56 | ― | 0.10% | 10.71% | 2756.39% | |
57 Neutral | ₹24.97B | 16.39 | ― | 0.11% | 19.47% | 11.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
42 Neutral | ₹19.90B | 391.08 | ― | 0.47% | 8.40% | ― |
* General Sector Average
IN:CAMLINFINE
Camlin Fine Sciences Limited
101.80
-118.70
-53.83%
IN:FCL
Fineotex Chemical Limited
57.76
34.12
144.34%
IN:GOCLCORP
GOCL Corporation Limited
443.20
96.40
27.80%
IN:KIRIINDUS
Kiri Industries Limited
537.65
-54.25
-9.17%
IN:NOCIL
NOCIL Limited
189.35
4.13
2.23%
IN:ROSSARI
Rossari Biotech Ltd
447.40
-196.98
-30.57%
Camlin Fine Sciences Limited Corporate Events
Camlin Fine Sciences Discloses Resignation of Senior R&D Executive
Jul 7, 2026
Camlin Fine Sciences Limited has announced the resignation of Mr. Anvarhusen Bilakhiya from his role as Vice President – Principal Scientist (RD), where he was designated as Senior Management Personnel. His resignation, attributed to persona...
Camlin Fine Sciences Schedules Investor Meet in Mumbai
Jun 28, 2026
Camlin Fine Sciences Limited, a specialty chemicals producer known for its fine chemicals and antioxidant solutions, caters to diverse end-markets including food, feed, and industrial segments in India and overseas. Its portfolio positions the com...
Camlin Fine Sciences Wins AMF Clearance for Mandatory Tender Offer on Vinpai
Jun 18, 2026
Camlin Fine Sciences Limited has strengthened its control over French ingredients company Vinpai, where it already holds 83.82% of the share capital and 80.85% of the voting rights, following a prior block acquisition and conversion of convertible...
Camlin Fine Sciences Shuts Diphenol Plant, Contains Fire Without Major Operational Impact
May 24, 2026
Camlin Fine Sciences has shut its diphenol plant at Dahej SEZ in Gujarat due to severe constraints in the availability and pricing of key raw materials amid current geopolitical and economic headwinds. The company has secured Hydroquinone imports ...
Camlin Fine Sciences Shuts Diphenol Plant After Fire, Sees No Material Hit to Operations
May 24, 2026
Camlin Fine Sciences has shut its diphenol plant at Dahej SEZ-II in Gujarat due to severe constraints in the availability and pricing of key raw materials amid geopolitical and economic pressures. The company has secured imported Hydroquinone and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.